NEW YORK - Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM), a company specializing in targeted radiotherapies, has launched a strategic initiative for the production of Actinium-225 (Ac-225), a medical isotope used in cancer treatment. The initiative aims to leverage Actinium's proprietary cyclotron-based manufacturing technology, which has demonstrated the potential for lower costs at commercial scale compared to current production methods.
Actinium-225, an alpha-particle emitter, is utilized in targeted radiotherapies for its ability to induce double-strand breaks in DNA, a mechanism against which there is no known resistance. The company's technology boasts a production of up to 100 mCi of Ac-225 per cycle with radiochemical purity over 99% and radioisotopic purity of 99.8%, without long-lived contaminants.
The company's Chairman and CEO, Sandesh Seth, expressed confidence in the scalability and efficiency of Actinium's method, emphasizing its ability to produce clinical-grade Ac-225 rapidly. The technology also enables the purification and recycling of Radium-226, the starting material, which could alleviate the current scarcity and high procurement costs of Ac-225.
Actinium's initiative comes at a time when the majority of Ac-225 is supplied by the United States Department of Energy (DOE), primarily for research purposes, with limited clinical-grade material available. The DOE is also exploring cyclotron production of Ac-225, a method that Actinium has been investing in and developing.
The company holds a robust intellectual property portfolio for its cyclotron-based production method, including 5 issued U.S. patents and 49 international patents. Actinium plans to make multi-million-dollar investments and pursue global collaborations to scale its technology and meet the growing demand for Ac-225, supporting both internal programs and the broader market.
Actinium's current pipeline includes advanced candidates like Iomab-B, aimed at bone marrow transplant conditioning, and Actimab-A, under pivotal development for acute myeloid leukemia. The company's focus on targeted radiotherapies aims to improve survival outcomes for patients who have exhausted existing oncology treatments.
This strategic move by Actinium Pharmaceuticals is based on a press release statement and reflects the company's commitment to innovation and addressing the needs of a significant patient population in the field of targeted radiotherapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.